Adenosine-induced neuroprotection

exerts its extracellular effects through four types of G-protein coupled receptors: A 1 , A 2A , A 2B and A 3 . Adenosine acts as an important regulator of metabolic processes. In the brain adenosine mediates prominent neuroprotective functions via the adenosine A 1 receptor. Whereas the pharmacological characteristics of the rat and human adenosine A 1 receptor have been intensively studied, the mouse adenosine A 1 receptor has not yet been characterized. Accordingly, we have cloned the mouse brain adenosine A 1 receptor and present here a pharmacological characterization of the mouse adenosine A 1 receptor using functional studies and radioligand binding assays. The results show that the binding affinities of several ligands for the mouse adenosine A 1 receptor are similar to the affinities for the rat and human adenosine A 1 receptor with some exceptions.

[1]  B. Fredholm,et al.  Signalling from adenosine receptors to mitogen-activated protein kinases. , 2003, Cellular signalling.

[2]  Adriaan P IJzerman,et al.  N6-cyclopentyl-2-(3-phenylaminocarbonyltriazene-1-yl)adenosine (TCPA), a very selective agonist with high affinity for the human adenosine A1 receptor. , 2003, Journal of medicinal chemistry.

[3]  A. Mendonça,et al.  Adenosine receptors in the nervous system: pathophysiological implications , 2002, Progress in Neurobiology.

[4]  B. Fredholm,et al.  Mice lacking the adenosine A1 receptor are anxious and aggressive, but are normal learners with reduced muscle strength and survival rate , 2002, The European journal of neuroscience.

[5]  B. Fredholm,et al.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. , 2001, Pharmacological reviews.

[6]  W. Flameng,et al.  Adenosine, adenosine receptors and myocardial protection: an updated overview. , 2001, Cardiovascular research.

[7]  R. Tabrizchi,et al.  Pharmacology of adenosine receptors in the vasculature. , 2001, Pharmacology & therapeutics.

[8]  B. Fredholm,et al.  Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[9]  A. Sauter,et al.  Ischemia‐induced neuronal expression of the microglia attracting chemokine secondary lymphoid‐tissue chemokine (SLC) , 2001, Glia.

[10]  R. Cunha,et al.  Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors , 2001, Neurochemistry International.

[11]  Helmut L. Haas,et al.  Functions of neuronal adenosine receptors , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.

[12]  M. Williams,et al.  Purinergic and pyrimidinergic receptors as potential drug targets. , 2000, Biochemical pharmacology.

[13]  H. Gavras,et al.  A role for the A3 adenosine receptor in determining tissue levels of cAMP and blood pressure: studies in knock-out mice. , 2000, Biochimica et biophysica acta.

[14]  R. Quinn,et al.  Adenosine receptors as potential therapeutic targets. , 1999, Drug discovery today.

[15]  B. Erlanger,et al.  A1 adenosine receptor of human and mouse adipose tissues: cloning, expression, and characterization. , 1999, Biochemical pharmacology.

[16]  K. Ravid,et al.  Characterization of the mouse A3 adenosine receptor gene: exon/intron organization and promoter activity. , 1999, Genomics.

[17]  B. Fredholm,et al.  Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. , 1999, Pharmacological reviews.

[18]  J. Nyce.  Insight into adenosine receptor function using antisense and gene-knockout approaches. , 1999, Trends in pharmacological sciences.

[19]  P. Schofield,et al.  Thermodynamics of full agonist, partial agonist, and antagonist binding to wild-type and mutant adenosine A1 receptors. , 1998, Biochemical pharmacology.

[20]  B. Fredholm,et al.  Comparative pharmacology of human adenosine receptor subtypes – characterization of stably transfected receptors in CHO cells , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[21]  S. Butcher,et al.  Species differences in brain adenosine A1 receptor pharmacology revealed by use of xanthine and pyrazolopyridine based antagonists , 1997, British journal of pharmacology.

[22]  S. Schiffmann,et al.  Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor , 1997, Nature.

[23]  Knut Biber,et al.  Adenosine A1 Receptor-Mediated Activation of Phospholipase C in Cultured Astrocytes Depends on the Level of Receptor Expression , 1997, The Journal of Neuroscience.

[24]  M. Edbrooke,et al.  Cloning and characterisation of the human adenosine A3 receptor gene , 1996, FEBS letters.

[25]  M. Danhof,et al.  8-substituted adenosine and theophylline-7-riboside analogues as potential partial agonists for the adenosine A1 receptor. , 1995, European journal of pharmacology.

[26]  F. Tan,et al.  Isolation and characterization of an avian A1 adenosine receptor gene and a related cDNA clone. , 1995, Biochemical Journal.

[27]  H. Akil,et al.  Cloning and characterization of a pharmacologically distinct A1 adenosine receptor from guinea pig brain. , 1994, Brain research. Molecular brain research.

[28]  A Villringer,et al.  Coupling of cerebral blood flow to neuronal activation: role of adenosine and nitric oxide. , 1994, The American journal of physiology.

[29]  G Burnstock,et al.  Nomenclature and Classification of Purinoceptors* , 2005 .

[30]  D. Marquardt,et al.  Cloning of two adenosine receptor subtypes from mouse bone marrow-derived mast cells. , 1994, Journal of immunology.

[31]  J. Shine,et al.  Molecular cloning and expression of an adenosine A2b receptor from human brain. , 1992, Biochemical and biophysical research communications.

[32]  G. Stiles,et al.  Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[33]  A. IJzerman,et al.  Influence of the molecular structure of N6-(omega-aminoalkyl)adenosines on adenosine receptor affinity and intrinsic activity. , 1989, European journal of pharmacology.

[34]  G Vassart,et al.  Selective amplification and cloning of four new members of the G protein-coupled receptor family. , 1989, Science.

[35]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[36]  M. Lohse,et al.  Interaction of barbiturates with adenosine receptors in rat brain , 1984, Naunyn-Schmiedeberg's Archives of Pharmacology.

[37]  A. Szent-Györgyi,et al.  The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart 1 , 1929, The Journal of physiology.

[38]  T. Stone.  Purines and neuroprotection. , 2002, Advances in experimental medicine and biology.

[39]  H. Akil,et al.  Cloning and characterization of a pharmacologically distinct A 1 adenosine receptor from guinea pig brain , 2002 .

[40]  J. Linden.  Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. , 2001, Annual review of pharmacology and toxicology.

[41]  G. Stiles,et al.  Adenosine receptor subtypes: characterization and therapeutic regulation. , 1995, Annual review of pharmacology and toxicology.

[42]  T. Dunwiddie.  The physiological role of adenosine in the central nervous system. , 1985, International review of neurobiology.